Sleep Changes in Parkinson’s Disease May Signal More Than Symptoms

Parkinson’s disease has long been framed as a disorder of movement, defined by tremor, rigidity, and the slow erosion of motor control. Yet a growing body of evidence suggests that some of the most clinically meaningful information about how the disease unfolds may lie in a system that neurologists have traditionally treated as secondary: sleep. A new letter published in the Journal of Clinical Sleep Medicine argues that the field should stop evaluating sleep in Parkinson’s disease as a simple list of symptoms and start treating sleep-related changes as markers of functional trajectories, the long-term paths along which patients lose or preserve their independence.

The letter, authored by Maghfirotul Lathifah of PGRI Adi Buana Surabaya University in Indonesia and published on 8 October 2026, responds directly to a prospective five-year follow-up study by Partinen and colleagues that tracked changes in sleep characteristics among people with Parkinson’s disease. That study, appearing in the same journal, is among the recent efforts to move beyond cross-sectional snapshots, which capture sleep problems at a single moment, and instead document how sleep evolves over years in the same patients. The distinction matters because sleep in Parkinson’s is not static. It shifts with disease progression, with medication adjustments, and with the emergence of non-motor complications that can precede or accompany motor decline.

The technical case for this shift in perspective rests on how sleep pathology in Parkinson’s disease is organized. Sleep disturbance in these patients is not a single phenomenon but a cluster of distinct mechanisms. There is REM sleep behavior disorder, in which the normal muscle paralysis of dream sleep fails and patients physically act out their dreams, sometimes violently. There is severe fragmentation of nighttime sleep, driven by a combination of neurodegeneration in brainstem arousal and sleep-regulating circuits, nocturnal motor symptoms such as rigidity and off-period dystonia, and medication effects. There is excessive daytime sleepiness, which may reflect both nighttime disruption and direct involvement of wake-promoting systems including the orexin neurons of the hypothalamus. Each of these phenomena has a different underlying anatomy, a different time course, and, crucially, a different relationship to prognosis.

This is where the concept of functional trajectories becomes central. In Parkinson’s research, functional status refers to a patient’s capacity to perform daily activities independently, from dressing and eating to walking and managing medication. Clinical trials have historically emphasized motor scores, but what patients and families experience most acutely is the loss of functional independence. If specific sleep abnormalities reliably predict the slope of that decline, they become powerful prognostic tools, capable of identifying patients who need earlier intervention, closer monitoring, or more aggressive management of non-motor symptoms.

The evidence for such a link is already substantial in at least one domain. A 2019 study by Kim and colleagues, cited in the letter, found that REM sleep behavior disorder predicted functional dependency in early Parkinson’s disease. This finding fits within a broader literature showing that REM sleep behavior disorder is one of the strongest predictors of an aggressive disease phenotype, associated with faster progression of both motor and cognitive impairment. The mechanistic logic is compelling: the brainstem circuits that fail in REM sleep behavior disorder, particularly structures such as the sublaterodorsal nucleus and its connections, are embedded in the same networks that degenerate as the disease spreads, and their early failure may index a more widespread and rapidly advancing pathological process.

The five-year follow-up data from Partinen and colleagues add a longitudinal dimension to this picture. By measuring sleep characteristics repeatedly over five years, the study can distinguish between sleep problems that appear early and remain stable and those that emerge or worsen as the disease progresses. That temporal information is exactly what is needed to test whether sleep changes are merely consequences of advancing disease or whether they actively track and predict functional decline. A symptom that worsens in parallel with functional loss, and that can be measured objectively with tools such as polysomnography and validated questionnaires, offers clinicians a window into disease trajectory that standard motor examinations may miss.

The letter also widens the lens beyond the patient. A 2022 systematic review and meta-analysis by Sprajcer and colleagues, published in BMJ Open, documented significant sleep disturbance in caregivers of individuals with parkinsonism. This finding underscores a point that is often lost in clinical discussions: sleep pathology in Parkinson’s disease radiates outward. Nocturnal wandering in REM sleep behavior disorder can injure both patient and bed partner. Frequent nighttime awakenings mean that caregivers, who are frequently spouses of advanced age, lose sleep night after night, with documented consequences for their own health, cognitive function, and capacity to provide care. Sleep outcomes in this disease are therefore not purely individual clinical endpoints; they are markers of household-level burden.

What would it mean, in practice, to reorient clinical care around functional trajectories rather than symptom checklists? First, it would elevate sleep assessment from an optional add-on to a core component of neurological evaluation. Structured screening for REM sleep behavior disorder, objective measurement of sleep fragmentation where feasible, and systematic tracking of daytime sleepiness would become routine, not because sleep complaints deserve relief on their own, though they clearly do, but because their evolution carries prognostic information. Second, it would change how clinical trials are designed. If sleep measures predict functional dependency, they become candidate surrogate endpoints, allowing new therapies to be evaluated against outcomes that matter to patients over shorter observation periods. Third, it would sharpen the search for mechanism, since different sleep phenotypes may correspond to different patterns of neurodegeneration and thus to different therapeutic targets.

The letter’s argument also carries a caution about interpretation. Sleep symptoms and functional decline could be linked in several ways that are not mutually exclusive. Sleep disruption may be a cause of functional deterioration, through mechanisms such as impaired overnight clearance of pathological proteins, worsened daytime cognition and motor performance, and accelerated neuroinflammation. Alternatively, both sleep change and functional decline may be parallel outputs of the same underlying neurodegenerative process, making sleep a sensitive but not causal indicator. Disentangling these possibilities requires longitudinal designs with repeated measures of both sleep and function, precisely the kind of evidence the five-year follow-up study begins to provide. The letter’s contribution is to insist that this interpretive work be framed in terms of trajectories, not static symptom counts.

For a disease that affects millions worldwide and for which no therapy has yet been proven to slow its progression, the search for early, measurable, and meaningful prognostic markers is one of the most urgent tasks in neurology. The argument advanced in this letter is that sleep, long relegated to the status of a quality-of-life complaint, deserves a seat at the center of that search. If the way a patient sleeps over five years can reveal the path their disease will take, then every night of disturbed sleep is not just a symptom to be managed but a signal to be read, and reading it early may change how, and how effectively, the disease is fought.

Subject of Research: The relationship between sleep disturbances and functional trajectories in Parkinson's disease

Article Title: Beyond sleep symptoms: why functional trajectories matter in Parkinson’s disease

Article References: Lathifah, M. (2026). Beyond sleep symptoms: why functional trajectories matter in Parkinson’s disease. Journal of Clinical Sleep Medicine, 22(1), Article 190. https://doi.org/10.1007/s44470-026-00205-5

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00205-5

Keywords: Parkinson's disease, sleep disorders, REM sleep behavior disorder, functional dependency, sleep fragmentation, excessive daytime sleepiness, neurodegeneration, caregiver burden, prognosis, longitudinal study, movement disorders, Journal of Clinical Sleep Medicine